Brokerages Anticipate Medidata Solutions, Inc. (NASDAQ:MDSO) Will Announce Earnings of $0.21 Per Share
Equities analysts forecast that Medidata Solutions, Inc. (NASDAQ:MDSO) will post earnings of $0.21 per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Medidata Solutions’ earnings, with the highest EPS estimate coming in at $0.22 and the lowest estimate coming in at $0.19. Medidata Solutions posted earnings per share of $0.16 during the same quarter last year, which indicates a positive year over year growth rate of 31.3%. The firm is expected to announce its next earnings results on Tuesday, October 24th.
On average, analysts expect that Medidata Solutions will report full-year earnings of $0.81 per share for the current year, with EPS estimates ranging from $0.76 to $0.87. For the next financial year, analysts anticipate that the firm will post earnings of $1.05 per share, with EPS estimates ranging from $1.01 to $1.15. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Medidata Solutions.
Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. Medidata Solutions had a net margin of 7.07% and a return on equity of 11.14%. The firm had revenue of $137.41 million for the quarter, compared to analyst estimates of $134.28 million. During the same quarter in the previous year, the business posted $0.24 EPS. The firm’s revenue was up 19.9% compared to the same quarter last year.
A number of research analysts recently issued reports on MDSO shares. Bank of America Corporation assumed coverage on shares of Medidata Solutions in a research note on Tuesday, June 6th. They issued a “buy” rating and a $85.00 target price on the stock. Zacks Investment Research raised shares of Medidata Solutions from a “hold” rating to a “buy” rating and set a $75.00 price target for the company in a report on Wednesday, May 3rd. Needham & Company LLC increased their price target on shares of Medidata Solutions from $65.00 to $75.00 and gave the company a “buy” rating in a report on Thursday, April 27th. Morgan Stanley set a $74.00 price target on shares of Medidata Solutions and gave the company a “buy” rating in a report on Wednesday, June 14th. Finally, BidaskClub raised shares of Medidata Solutions from a “hold” rating to a “buy” rating in a report on Wednesday, June 21st. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Medidata Solutions presently has a consensus rating of “Buy” and an average target price of $75.83.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/20/brokerages-anticipate-medidata-solutions-inc-nasdaqmdso-will-announce-earnings-of-0-21-per-share.html.
Medidata Solutions (NASDAQ:MDSO) opened at 76.51 on Thursday. The firm has a 50-day moving average of $77.40 and a 200-day moving average of $63.50. Medidata Solutions has a one year low of $46.10 and a one year high of $85.92. The firm has a market cap of $4.31 billion, a price-to-earnings ratio of 129.90 and a beta of 1.81.
In other news, EVP Michael I. Otner sold 7,500 shares of the firm’s stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $66.39, for a total transaction of $497,925.00. Following the completion of the transaction, the executive vice president now directly owns 78,419 shares of the company’s stock, valued at approximately $5,206,237.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert Taylor sold 5,639 shares of the firm’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $73.46, for a total transaction of $414,240.94. Following the transaction, the director now directly owns 54,372 shares of the company’s stock, valued at $3,994,167.12. The disclosure for this sale can be found here. Insiders have sold a total of 18,139 shares of company stock valued at $1,259,466 over the last ninety days. 5.80% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in MDSO. Clearbridge Investments LLC increased its position in Medidata Solutions by 61.4% in the first quarter. Clearbridge Investments LLC now owns 2,449,038 shares of the company’s stock worth $141,285,000 after buying an additional 931,729 shares during the last quarter. Norges Bank acquired a new position in Medidata Solutions during the fourth quarter worth approximately $35,052,000. Renaissance Technologies LLC increased its position in Medidata Solutions by 562.8% in the first quarter. Renaissance Technologies LLC now owns 396,992 shares of the company’s stock worth $22,902,000 after buying an additional 337,098 shares during the last quarter. Teachers Advisors LLC increased its position in Medidata Solutions by 254.0% in the first quarter. Teachers Advisors LLC now owns 371,554 shares of the company’s stock worth $21,435,000 after buying an additional 266,606 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Medidata Solutions by 5.1% in the first quarter. Vanguard Group Inc. now owns 4,874,974 shares of the company’s stock worth $281,237,000 after buying an additional 235,190 shares during the last quarter.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.